
The continuous intravenous infusion of zzso may control terminal cancer pain zzso by conventional narcotic zzso A retrospective review was conducted of the medical records of 79 terminal cancer patients who received a total of 84 intravenous zzso zzso Data were recorded on zzso zzso pain control, adverse effects, duration of infusion, and zzso medication zzso zzso duration varied from less than 24 hours to 162 days zzso 7 zzso zzso dosage ranged from zzso to 300 zzso All patients experienced an improvement in baseline pain zzso however, 54 percent required additional medication to enhance zzso Serious adverse effects, including marked zzso hallucinations, zzso and respiratory depression, were recorded in 14 zzso These effects may be a reason for reducing the zzso zzso for the use of continuous intravenous zzso infusions are zzso zzso pain assessment, zzso dosage zzso and monitoring of adverse effects are essential to insure the safe and effective use of these zzso 

